Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)
Status:
Not yet recruiting
Trial end date:
2026-06-30
Target enrollment:
Participant gender:
Summary
This is an open label, phase II study evaluating the efficacy and safety of trastuzumab
combined with oral chemotherapy (capecitabine or vinorelbine) in patients with HER-2 positive
stage I breast cancer.